ERBB2 and breast carcinoma: Patients with HER2+ breast cancer had higher serum miR-21 median levels than patients with HER2− breast cancer (17.22 vs. 12.37, p = 0.044) and HDs (17.22 vs. 8.40, p = 0.001).